Smith & Nephew(US:SNN)2019-10-31 22:34Q3 2019 Financial Performance - Smith+Nephew's Q3 revenue reached $1,246 million, reflecting a +4.0% underlying growth and +6.5% reported growth[6, 11] - Orthopaedics franchise revenue was $524 million, with an underlying growth of +3.4%[7, 15] - Sports Medicine & ENT franchise revenue amounted to $365 million, showing an underlying growth of +6.9%[8, 19] - Advanced Wound Management franchise revenue was $357 million, with an underlying growth of +2.1%[7, 22] Geographical Performance - US revenue reached $624 million, representing a growth of +2.7%[12, 13] - Other Established Markets generated $382 million in revenue, experiencing a decline of -0.3%[12, 13] - Emerging Markets revenue was $240 million, demonstrating a growth of +16.0%[12, 14] Orthopaedics Sub-Franchise Performance - Knees sub-franchise showed a global growth of +4.6%, with US at +1.7% and OUS at +8.6%[15] - Hips sub-franchise grew globally by +2.6%, with US at +2.2% and OUS at +3.1%[15] - Trauma sub-franchise experienced a growth of +2.2%[15] Sports Medicine & ENT Sub-Franchise Performance - Sports Medicine Joint Repair (SMJR) grew by +12.2%[19] - Arthroscopic Enabling Technologies (AET) grew by +0.8%[19] - ENT grew by +5.3%[19] Advanced Wound Management Sub-Franchise Performance - Advanced Wound Care (AWC) declined by -1.8%[22] - Advanced Wound Bioactives (AWB) grew by +2.1%[22] - Advanced Wound Devices (AWD) grew significantly by +15.4%[22] 2019 Guidance - The company projects sales growth with an underlying rate of 3.5% to 4.5% and a reported rate of 3.9% to 4.9%[48] - The trading profit margin is expected to be around 22.8%[48]